Skip to main content

Takeda Pharmaceutical

Takeda Pharmaceutical Company Ltd is a Japanese biopharmaceutical company focused on the research, development, and commercialization of prescription medicines. The enterprise structures its business operations around five core therapeutic areas: gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Primary revenue drivers include proprietary prescription drugs such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, and plasma products. Takeda occupies a leading position as the largest pharmaceutical enterprise in Asia and ranks among the top global drug makers by revenue. Its principal end markets comprise healthcare providers, hospitals, and retail pharmacies across North America, Europe, Japan, and emerging markets. The company is headquartered in Tokyo, Japan, and maintains primary listings on the Tokyo Stock Exchange and New York Stock Exchange.

54 of the funds FundTelligence covers report a position in Takeda Pharmaceutical.

Sector
Health Care
Country
Japan
Funds holding it
54

Funds holding Takeda Pharmaceutical

Showing the 8 largest of 54 funds holding it.

Loading...